Similar documents
1 見出し1,12ポ,日本語ゴシック,英語Arial,段落後は6ポの設定です

(別添様式)


特殊病態下感染症における抗菌薬治験の手引き作成委員会報告書(案)

胆石症

本文.indd

要望番号 ;Ⅱ-183 未承認薬 適応外薬の要望 ( 別添様式 ) 1. 要望内容に関連する事項 要望者学会 ( 該当する ( 学会名 ; 日本感染症学会 ) ものにチェックする ) 患者団体 ( 患者団体名 ; ) 個人 ( 氏名 ; ) 優先順位 1 位 ( 全 8 要望中 ) 要望する医薬品

2009年133巻3号3月号.indb

untitled


.K.C.h...C...ren

終末期癌患者に対する 輸液治療の是非

橡

untitled

164 SDD & SOD SDD E100 mg 80 mg B500 mg 2 E 2 B 48 /59 81 SDD SOD 10 /63 16 RCT RCT 1992 Gastinne 15 ICU 445 SDD E100 mg 80 mg B 10

終末期の呼吸困難症状への対応*松坂最終修正

C/NC : committed/noncommitted

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 2 Apr NTT NTT


et al No To Shinkei Clin Neurol Neurology et al J Neurosurg et al Arch Neurol et al Angiology

「諸雑公文書」整理の中間報告

Rinku General Medical Center

CLINICAL STUDY 2011 Double blind, randomized, cross over, controlled clinical trial of Symbosial (NaCl + Chitosan 3%) vs NaCl on high blood pressure p

01.浅野.ppt

食道がん化学放射線療法後のsalvage手術

小児感染免疫第23巻第1号

untitled

がん患者の終末期ケアにおける通所リハビリテーションの役割 介護保険によるがん終末期ケアの可能性

untitled

37, 9-14, 2017 : cefcapene piperacillin 3 CT Clostridium difficile CD vancomycin CD 7 Clostridium difficile CD CD associate

8 The Bulletin of Meiji University of Integrative Medicine API II 61 ASO X 11 7 X-4 6 X m 5 X-2 4 X 3 9 X 11 7 API 0.84 ASO X 1 1 MR-angio

MV X 5 6 Common Terminology Criteria for Adverse Events Grade 1 Grade Gy 16 QOL QOL 5 6 7, 8 9, VOL.3 NO

SBP hospitalist network.key

<30332D D8CB492982D FC95E490E690B62D8FAC8FBC96BE90E690B62E706466>

Understanding Stem Cell Transplant 2007

資料 3 1 医療上の必要性に係る基準 への該当性に関する専門作業班 (WG) の評価 < 代謝 その他 WG> 目次 <その他分野 ( 消化器官用薬 解毒剤 その他 )> 小児分野 医療上の必要性の基準に該当すると考えられた品目 との関係本邦における適応外薬ミコフェノール酸モフェチル ( 要望番号

慢性膵炎


sick contact1l

短信-1.PDF

untitled

*4 Drug Delivery System original article Cytodegenerative and growth-inhibitory effects on LY-80 cells by methotrexate and 5-fluorouracil in combinati


32 1 BRONJ BRONJ II BRONJ BRONJ 4 BP BRONJ 6 1 III BP BRONJ


PubMed 1. CD-ROM MEDLINE MeSH PubMed 2. Automatic Term Mapping MeSH 3. Related Article MeSH Browser MeSH PreMEDLINE MeSH -2-

Ⅲ 章推奨 4 便秘 下剤は, がん患者の便秘を改善させるか? 関連する臨床疑問 9 1 浸透圧性下剤 ( 酸化マグネシウム, ラクツロース ) は, がん患者の便秘を改善させるか? 9 2 大腸刺激性下剤 ( センナ, ピコスルファート ) は, がん患者の便秘を改善させるか? 9 3 ルビプロス


Fig. 1 Clinical findings and extent of inflammation area in female urethrocystitis Fig. 2 Classification and distribution of female patients with blad

病院感染対策ガイドライン(結核症)


untitled

日本皮膚科学会雑誌第122巻第2号

14UNAIDS HIV 39% i 9 ii9iii UNAIDS x.9x.9x1= ?? UNAIDS % 77%8% 44.7x.77x.8x1=

Cytokine-adsorbing hemofilter:バクスター セプザイリス(AN69ST膜hemofilter)


臨床神経 indd


Gynecologic Oncology Trial and Investigation Consortium GOTIC-002


説明書82:妊娠と抗てんかん薬★★.PPT

untitled

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

平成14年10月3日(日)

化学療法剤の適切な使い方について

60周年記念 記念誌/扉・扉裏・中扉・資料扉・名簿扉



›¼’à”v“lŠÍ1−ª

特別プログラム

8 浜根知恵(p191‐203)204白/p191‐203

★表紙-背幅5.5mm/表紙

SBI損保の自動車保険 重要事項説明書


表紙(背幅8.5mm)/背幅8.5mm


2

_ZEI-1022_fiÁŁÊ−é›æ-’‘Ä


1 鵜澤幸弘(p7‐26)/性同一障害 p7‐26

広報あつぎ-1月15日号-1面12.indd

untitled

A4_元

本文/A6180A

150220_通し


本文/YAY180B


研究紀要 第22号 (分割版 その7)

S \1.E4

学内広報 No.1224


本文(縦)/YAZ149T

48 で持続静注を行い, 持続静注中の再発 (breakthrough seizure) には 1 ~2 mg/kg の ボーラス追加投与を行い,12 時間おきに 0.5~1 mg/kg/ 時ずつ増量する バーストサプレッションは 12~48 時間維持する 4, 5 チアミラール ( 持続静注は適応

日本皮膚科学会雑誌第121巻第11号


AUTONOMIC FUNCTIONAL STATE IN RENAL TUBERCULOSIS REPORT III. SERUM CHOLINESTERASE ACTIVITY IN RENAL TUBERCULOSIS Sanai Yamamura The Department of Urol

Therapy for Asthenopia in Cases of Convergence Insufficiency Hiroko TAKASAKI, C.O.J., Nobuko INAGAMI, C.O.J., and Kayoko TAKENAWA, C.O.J.. Orthoptic c



Transcription:

fl:a-221 fr:(a_222 [-O-72 3 li-o)-80

u-o-40 u-o-74

[-O-16 III-O-i3

lr-{o-2e 1 tr-g2e.3 rrr-g3e

fi-o-zs

rrr{tsr8 [+1e ll1g41 )isatracurium besylate besylate li-gr2

-omitapide iegenon )harmaceuticals #it Eff

-omustine llinatumomab Roche Ranbaxy Mylan Pharmaceuticals Teva Pharmaceuticals Douglas Pharmaceuticals Dr Reddy's Laboratories tf t^'y^,a) tirivl> Fludarabine 1 E E30mc/m2t3O1} D,lt i' tj (s E ffi A ;fi ffi flft 6 te +f 6 "

)ropranolol

4\!E

levosimendan Orion

levosimendan Orion

m-e-26 l,500mg l,800mg 2,l00mg 2,400mg 900mg l,200mg I,500mg

m-e-60 )zpzr>

m-o-ot

American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis') (tjt. IACR )J'4 F 7 4 > I ) l) Appel GB, et al. Mycophenolate mofetil versus cyclophosphamide for

l) Appet GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol.

Madenanc? MMF Dose pcr Body Surface Arco (mg/mtday)

Recommendations for the pharmacological management of neuropathic pain: an overview and literature updater0) Neuropathic pain: The pharmacological management of neuropathic pain in adults in r' non-specialist settings

Bansal D et al. Amitriptyline vs. pregabalin in painful diabetic neuropathy: a randomized double blind clinical trial. Diabet Med 2009',26: l0l9-26tt) Biesbroeck R et al. A double-blind comparison of topical capsaicirr and oralamitriptyline in painfuldiabetic neuropathy. Adv Ther 1995; 12: lll-20t2) Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997 l3: t-r r t l-l) )z I-J I Graff-Radford SB et al. Amitripfyline and fluphenazine in the treatment of postherpetic neuralgia. Clin J Pain 2000: l6: 188-9214' Kalso E et al. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain 1996; 64: 293-302t51 Kieburtz K et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. AIDS Clinical Trial Group 242 Protocol Team. Neurology 1998; 5 I : I 682-816) Max MB et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 142142t7) Morello CM et al. Randomize double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intem Med 1999: 159: 193 l-7r8) Vrethem M et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997; lj: 313-23rq' Watson CP et al. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology 1998; 5 l: 1166-7120)

EFNS guidelines on pharmacological treatment of neuropathic pain '" l) Vrethem M et al. A comparison of amitriptyline and maprotiline in the treatment of painful polyneuropathy in diabetics and nondiabetics. Clin J Pain 1997: 13:31323te) 2) Watson CP et al. Amitriptyline versus maprotiline in postlrerpetic neuralgia: a randomized double-blind, crossover trial. Pain 1992:, 48: 294622) 3) Mercadante S et al. Amitriptyline in neuropathicancer pain in patients on morphine therapy: a randomized placebo-controlled, double-blind crossover study. Tumo ri 2002; 88: 239422t\ 4) Kalso E et al. Amitriptyline effectively relieves neuropathic pain followine treatment of breast cancer. Pain 1996: 64:293-302ts' Pharmacological management of chronic neuropathic pain - Consensus statement and euidelines from the Canadian Pain Sociefv2s)

Recommendations for the phannacological management of neuropathic pain: an overview and literature updatel0)

3) Bowsher D. The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: randomized, double-blind, placebo-controlled trial. J Pain Symptom Manage 1997. 13:327-31t3)

6) Max MB et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427_32t7)

PucEBo + DRUG -+ doc-arni (10 ptsl.o. ploc-[o? (11 pt3)

7) Morello CM et al. Randomize double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch lntern Med 1999;159: 1931-7t8) r Crossover Fronr Amitriptyline t0 Gdbaprenliir o Crossover From Gabapentin i0 Amitriotylire L'kCrrt;